What is Actio?
Actio Biosciences is a biotechnology innovator dedicated to the discovery and development of life-changing treatments. By identifying shared biological mechanisms across diverse disease states, the company creates targeted therapies that address the root causes of illness rather than merely managing symptoms. This platform-based approach to drug discovery positions Actio Biosciences at the intersection of genetics and clinical application, enabling a more efficient path to market for novel therapeutics. The firm's strategic focus on precision medicine allows it to navigate the complexities of both rare and common diseases, creating a diversified and high-impact portfolio.
How much funding has Actio raised?
Actio has raised a total of $121M across 2 funding rounds:
Series A
$55M
Series B
$66M
Series A (2023): $55M with participation from Canaan, Deerfield, and EcoR1 Capital
Series B (2025): $66M led by Droia, Deerfield Management, Regeneron Ventures, Canaan, and Euclidean
Key Investors in Actio
Droia
Droia Ventures is a specialist investor, dedicated to making an impact and saving patient lives by investing in the most promising life science companies.
Deerfield Management
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy, supporting companies across the healthcare ecosystem.
Regeneron Ventures
Regeneron Ventures is focused on investing in innovative biotechnology and pharmaceutical companies to support the development of groundbreaking therapies and improve patient outcomes.
What's next for Actio?
With the successful closure of its latest financing round, Actio Biosciences is well-positioned to transition into a more mature phase of clinical development. The strategic allocation of this capital will likely focus on advancing lead candidates through regulatory milestones and expanding the company's proprietary genetic research platform. As the firm continues to refine its therapeutic focus, stakeholders anticipate further data readouts that could validate its core hypothesis regarding shared disease biology. The company remains a key player to watch as it seeks to transform the standard of care for patients suffering from complex, genetically-driven conditions.
See full Actio company page
